Curated for Orthogate.org Members

Weekend Recap | October 9–12, 2026. This edition covers the extended window from Friday, October 9 through Monday, October 12, 2026.

EXECUTIVE SUMMARY

• FDA Issues Draft Guidance on Robotically-Assisted Surgical Devices: As analyzed by Orthopedics This Week, FDA’s September 25, 2026 draft guidance on premarket submissions for robotically-assisted surgical devices carries an orthopaedic caveat tied to how orthopaedic robotic platforms are classified, including stereotaxic instruments under product code OLO.
• Brixton Biosciences ReneuRx (Neural Ice) Granted De Novo: Reported by Orthopedics This Week, FDA granted De Novo authorization to ReneuRx, creating a new Class II category (21 CFR 888.3048) for injectable devices that treat musculoskeletal pain through thermal energy exchange, with knee osteoarthritis pain as the focus.
• 4WEB and NuVasive Trade Wins in 3D-Printed Implant Patent Fight: Covered by Orthopedics This Week, the design patent litigation between 4WEB Medical and NuVasive (owned by Globus Medical) over 3D-printed spinal implants has produced rulings favoring each side.
• SI-BONE iFuse Granite Onyx Implant System Cleared: SI-BONE, Inc. received FDA 510(k) clearance (K262067) for the iFuse Granite Onyx Implant System, classified as a thoracolumbosacral pedicle screw system.
• Corin Unity Knee Cementless CR Femur Cleared: Corin, Ltd. received FDA 510(k) clearance (K261275) for the Unity Knee Cementless CR Femur, extending its Unity Total Knee System with an uncemented porous-coated femoral option.

DAILY ANNOUNCEMENTS BY CATEGORY

Surgical Robotics, AI & Navigation

U.S. FDA — Draft Guidance: “Robotically-Assisted Surgical Devices – Premarket Submissions”

• Summary: On September 25, 2026, FDA announced draft guidance titled “Robotically-Assisted Surgical Devices – Premarket Submissions,” setting out the agency’s recommendations for the content of premarket submissions for robotic surgical systems. Orthopedics This Week’s analysis flags an orthopaedic asterisk in the draft, centered on how orthopaedic robotic and navigation platforms regulated as stereotaxic instruments (product code OLO) relate to the guidance.
• Key Details:
  • Device/System Name: Robotically-Assisted Surgical Devices (RASDs); orthopaedic stereotaxic instruments (product code OLO)
  • Status: FDA Draft Guidance (announced September 25, 2026; not yet final)
  • Clinical Significance: Arthroplasty and spine robotics manufacturers will need to determine whether their platforms fall within the draft’s scope; the final guidance could shape the premarket evidence expected for next-generation orthopaedic robotic systems.
• Original Source: Orthopedics This Week

Corporate, M&A & Regulatory

Brixton Biosciences — FDA Grants De Novo Authorization to ReneuRx (Neural Ice), Opening a New Injectable Pain Category

• Summary: On August 21, 2026, FDA granted De Novo authorization to Brixton Biosciences’ ReneuRx (Neural Ice), establishing a new Class II classification under 21 CFR 888.3048 for injectable devices that treat musculoskeletal pain through thermal energy exchange. The authorization, highlighted this week by Orthopedics This Week, centers on injectable cryoneurolysis for knee osteoarthritis pain.
• Key Details:
  • Device/System Name: ReneuRx (Neural Ice)
  • Status: FDA De Novo Authorization (Class II; 21 CFR 888.3048; August 21, 2026)
  • Clinical Significance: Adds a drug-free, injectable, non-surgical option to the knee osteoarthritis pain pathway, and the new classification gives follow-on thermal injectable devices a 510(k) route to market.
• Original Source: Orthopedics This Week

Spine & Orthobiologics

4WEB Medical / NuVasive (Globus Medical) — Both Sides Score Wins in 3D-Printed Implant Design Patent Fight

• Summary: The legal battle between 4WEB Medical and NuVasive, now owned by Globus Medical, over 3D-printed spinal implant designs has produced rulings favoring each side. Orthopedics This Week’s coverage points to Daubert expert-testimony challenges and NuVasive’s Modulus 3D-printed implant line as key elements of the case.
• Key Details:
  • Device/System Name: 3D-printed spinal implant designs; NuVasive Modulus
  • Status: Ongoing Design Patent Litigation (mixed pretrial rulings)
  • Clinical Significance: The outcome may shape the intellectual property landscape and competitive availability of additively manufactured interbody implants used in spinal fusion.
• Original Source: Orthopedics This Week

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES — ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2–4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.